Status:
TERMINATED
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
Lead Sponsor:
Indiana University
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding...
Eligibility Criteria
Inclusion
- Ability to understand and willingness to sign a witnessed, informed consent and authorization for the release of health information.
- Patients with a diagnosis of relapsed Stage IV renal cell cancer that are medically unresponsive to prior treatment or surgically unresectable and with metastases that fall within the PET/CT field-of-view that can include the heart.
- Being considered for systemic therapy with Sunitinib
Exclusion
- Women who are pregnant, breast-feeding, or of childbearing potential and not using birth control
- Having no telephone or a reliable way in which study personal can contact them
- Subjects who are claustrophobic and cannot tolerate imaging procedures
- Subjects who weigh \> 350 lb. (upper weight limit of scanner beds)
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01502228
Start Date
October 1 2011
End Date
February 1 2014
Last Update
March 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States, 46202